PALO ALTO, Calif., June 5 /PRNewswire/ -- Sinexus, Inc. made two key announcements today: Lisa Earnhardt joined as President & CEO and PTV Sciences has teamed up with their premier VC backers in a $20 Million Series B financing. This financing round was led by PTV Sciences along with existing investors Kleiner Perkins Caufield & Byers and U.S. Venture Partners.
Earnhardt joined Sinexus in March 2008. Well-known for her leadership in the medical device industry, Lisa most recently was the President of Boston Scientific's Cardiac Surgery division. She played an instrumental role in the sale of that business to the Getinge Group in January 2008. Previously, she held a variety of sales and marketing positions within Guidant's Cardiac Rhythm Management and Cardiac Surgery divisions. Lisa has a B.S. in Industrial Engineering from Stanford University and an M.B.A. from Northwestern's Kellogg School of Management, where she serves on the Advisory Board.
PTV Sciences, based in Austin, Texas, is a leading life science venture capital firm. Joining the Board of Directors of Sinexus will be Evan Melrose, M.D. Managing Director of PTV Sciences.
"We are delighted that PTV Sciences and Dr. Melrose have joined with us to bring our innovative chronic sinusitis therapy to market," said Earnhardt. "Sinexus will benefit from PTV's domain expertise and passion for advancing patient care."
"Sinexus has assembled a strong team that is developing compelling solutions for Ear, Nose & Throat physicians and their patients. We look forward to joining the Sinexus team," added Dr. Melrose.
Sinexus, Inc. (http://www.sinexusinc.com) is a development-stage medical device company that is pioneering novel therapies for Ear, Nose & Throat (ENT) physicians to utilize in providing improved treatment for their patients. Sinexus' initial focus is treating patients with Chronic Rhinosinusitis, a debilitating chronic condition that affects one out of seven adults in the United States.
About PTV Sciences
PTV Sciences (http://www.ptvsciences.com), founded in 2003, is a leading life science venture capital firm focused on building industry leading companies and investing in extraordinary people. PTV Sciences has a team of investment professionals and 13 venture partners representing the leading clinicians, scientists, academic institutions, and entrepreneurs. PTV Sciences has offices in Austin and Houston, Texas.
About Kleiner Perkins Caufield & Byers
Since its founding in 1972, Kleiner Perkins Caufield & Byers (KPCB, http://www.kpcb.com) has backed entrepreneurs in over 500 ventures, including AOL, Amazon.com, Citrix, Compaq Computer, Electronic Arts, Genentech, Genomic Health, Google, Intuit, Juniper Networks, Netscape, Lotus, Sun Microsystems, Symantec, VeriSign and Xilinx. In February 2008, KPCB announced its $100 million iFund initiative targeted at innovation in the Apple iPhone and iTouch platform. KPCB portfolio companies employ more than 250,000 people. More than 150 of the firm's portfolio companies have gone public. Many other ventures have achieved success through mergers and acquisitions.
About U.S. Venture Partners
U.S. Venture Partners (USVP, http://www.usvp.com) is a leading Silicon Valley-based venture capital firm, dedicated to helping entrepreneurs build world-class companies that are leaders in their industry. Since 1981, when it was founded, USVP has raised a total of more than $2.9 billion in nine venture capital funds and invested in more than 390 early stage companies, 74 of which to date have become public companies by IPO with an aggregate current market value in excess of $90 billion. USVP focuses on early stage opportunities in sectors where the Partners have the domain expertise, operating experience and network of relationships to provide meaningful contribution to the success of the enterprise. These sectors include digital communications and networking systems, Internet and eCommerce infrastructure, semiconductors and optical components, enterprise and technical software, and medical devices and biopharmaceuticals.
SOURCE Sinexus, Inc.